| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.15B | 9.81B | 8.38B | 5.59B | 4.81B | 2.61B |
| Gross Profit | 6.25B | 5.67B | 4.69B | 3.14B | 3.05B | 1.66B |
| EBITDA | -1.42B | -1.75B | 67.00M | 359.00M | 90.00M | -441.13M |
| Net Income | -2.21B | -2.58B | -610.00M | -141.00M | -137.00M | -592.69M |
Balance Sheet | ||||||
| Total Assets | 7.46B | 7.02B | 9.93B | 7.94B | 7.87B | 3.69B |
| Cash, Cash Equivalents and Short-Term Investments | 3.85B | 3.01B | 3.49B | 5.23B | 5.54B | 2.34B |
| Total Debt | 2.48B | 2.55B | 2.85B | 310.00M | 345.00M | 815.00M |
| Total Liabilities | 4.35B | 4.48B | 4.95B | 1.32B | 1.23B | 1.30B |
| Stockholders Equity | 3.02B | 2.46B | 4.93B | 6.54B | 6.59B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 505.00M | -1.12B | -843.00M | -445.00M | -1.09B |
| Operating Cash Flow | 0.00 | 621.00M | -197.00M | 71.00M | 24.00M | -528.13M |
| Investing Cash Flow | 0.00 | -880.00M | -2.95B | -483.00M | -701.00M | -572.57M |
| Financing Cash Flow | 0.00 | -221.00M | 1.41B | 105.00M | 3.88B | 1.80B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ¥13.33B | 87.84 | ― | ― | 25.41% | 9.69% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | ¥63.30B | -43.44 | ― | ― | 8.98% | -581.59% | |
56 Neutral | ¥4.24B | 23.89 | ― | ― | 10.43% | -65.78% | |
56 Neutral | ¥10.23B | 73.76 | ― | ― | 60.41% | -27.67% | |
52 Neutral | ¥12.93B | -173.88 | ― | ― | 16.29% | 93.98% | |
44 Neutral | ¥25.14B | -49.19 | ― | ― | 36.08% | -7.71% |
ExaWizards Inc. has approved a simplified absorption-type company split to transfer its HR Tech business, built around the exaBase DX Assessment & Learning talent development service and newer AX-focused programs, to its wholly owned subsidiary Exa Enterprise AI Inc. The move responds to a shift in market demand from digital transformation to AI transformation, as clients seek more advanced AI utilization and talent development solutions.
By consolidating overlapping customer bases and service offerings into Exa Enterprise AI, the group expects faster decision-making, higher development speed, and stronger synergies across planning, development, and sales. The restructuring, effective April 1, 2026, leaves share capital and stock acquisition rights at the parent unchanged and is intended to optimize resource allocation and support sustainable growth in AI-driven HR solutions and enterprise productivity tools.
The most recent analyst rating on (JP:4259) stock is a Buy with a Yen1020.00 price target. To see the full list of analyst forecasts on ExaWizards Inc. stock, see the JP:4259 Stock Forecast page.
ExaWizards Inc. released its financial results presentation for the third quarter of the fiscal year ending March 2026. The materials outline consolidated financial performance, segment progress, and business updates, indicating a structured disclosure of how each business area is advancing and how the company is tracking against its strategic and operational objectives.
The document highlights an executive summary of Q3, detailed consolidated results, and an overview of business segment developments. It also points to ongoing business updates and appendices that frame the company’s current performance trajectory, providing stakeholders with a snapshot of operational progress and the state of its AI-focused business portfolio.
The most recent analyst rating on (JP:4259) stock is a Buy with a Yen1020.00 price target. To see the full list of analyst forecasts on ExaWizards Inc. stock, see the JP:4259 Stock Forecast page.
ExaWizards Inc. reported consolidated net sales of ¥8.35 billion for the nine months ended December 31, 2025, up 17.1% year on year, and moved into profitability with operating profit of ¥1.03 billion and profit attributable to owners of parent of ¥695 million, reversing a loss in the prior-year period. The company also strengthened its financial position, with total assets rising to ¥8.34 billion and the equity ratio improving to 44.0%, while maintaining a no-dividend policy for the fiscal year.
The company revised its full-year forecast, now expecting net sales of ¥11.8 billion, a 20.3% increase from the previous year, and operating profit of ¥1.35 billion, signaling confidence in sustained growth and margin improvement. These results and forecasts suggest a successful scaling of its AI-related services business, enhanced capital structure, and improving shareholder value prospects despite the continued decision not to return cash via dividends at this stage.
The most recent analyst rating on (JP:4259) stock is a Buy with a Yen1020.00 price target. To see the full list of analyst forecasts on ExaWizards Inc. stock, see the JP:4259 Stock Forecast page.
ExaWizards’ wholly owned subsidiary ExaMD Inc. has submitted a clinical trial notification to Japan’s Pharmaceuticals and Medical Devices Agency for its AI-powered cognitive function diagnostic support software, a Software as a Medical Device designated by the health ministry for priority review. The trial, targeting up to 100 participants over three months, will assess the tool’s ability to classify individuals as cognitively normal or suspected of cognitive decline using about one minute of free conversation, comparing estimated MMSE scores to measured results while monitoring safety, and the company has already factored the associated costs into its current fiscal year investment plans, indicating no change to its full-year earnings forecast at this stage.
The most recent analyst rating on (JP:4259) stock is a Hold with a Yen840.00 price target. To see the full list of analyst forecasts on ExaWizards Inc. stock, see the JP:4259 Stock Forecast page.